Science

Jul 8, 2025, 09:43

Myeloma Paper of the Day, July 8th, Suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day:

Study of patients with symptomatic Waldenström macroglobulinemia finds cumulative SPM incidence 4.0% and 7.2% at 5 and 10 yrs; transformation to high-grade NHL accounting for death from WM or other cause at 5 and 10 yrs was 2.1% and 3.4%.”

Title: Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia

Authors: Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Charalampos Filippatos, Marie Christine Kyrtsonis, Nikolaos Giannakoulas, Emmanouil Spanoudakis, Sosanna Delimpasi, Michalis Michael, Stavroula Giannouli, Georgia Kaiafa, Eirini Katodritou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

You can read the Full Article in Clinical Lymphoma, Myeloma and Leukemia.

Myeloma Paper of the Day, July 8th, Suggested by Robert Orlowski

More posts featuring Robert Orlowski.

cancer Charalampos Filippatos Efstathios Kastritis Eirini Katodritou Emmanouil Spanoudakis Evangelos Terpos Georgia Kaiafa Ioannis Ntanasis-Stathopoulos Maria Gavriatopoulou Marie Christine Kyrtsonis Meletios-Athanasios Dimopoulos Michalis Michael Myeloma Myeloma Paper of the Day Nikolaos Giannakoulas OncoDaily Oncology Robert Orlowski Sosanna Delimpasi Stavroula Giannouli Vasiliki Spiliopoulou Waldenstroms Macroglobulinemia

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Writer?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...